Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDITOXIN in Benign Masseteric Hypertrophy
NCT03452345Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Meditoxin in benign masseteric hypertrophy (BMH), sponsored by Medytox Inc.. Started Apr 2018; status: completed.
02
Drugs
Meditoxin
03
Conditions
benign masseteric hypertrophy (BMH)
Beyond the preview
Go deeper on NCT03452345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452345.